

---

## Contents

Abbreviations	iv
List of Tables	vi
List of Figures	viii

<b>Section</b>	<b>Page No.</b>
----------------	-----------------

### **Chapter 1: INTRODUCTION**

1.1. Antibiotics and their development	1
1.2. Curcumin as antimicrobial agent	3
1.3. Anti-malarial drugs and their development	4
1.4. New Targets for anti-malarial drug	6
1.5. Curcumin as anti-malarial	8
1.6. Malaria burden in India	9
1.7. Curcumin ring and its biological activities	10
1.8. Molecular docking	12
1.9. Quantitative Structure Activity Relationship (QSAR)	12
1.9.1. Role of QSAR in Drug Design	13
1.9.2. QSAR Descriptors	13
1.10. Matrix metalloproteinase (MMPs)	14
1.10.1. Biological function	14
1.10.2. Role in pathological processes	14
1.10.3. Curcumin and MMPs	15

### **Chapter 2: LITERATURE REVIEW**

2.1. Microbial Infections	16
2.2. Curcumin as antimicrobial agent	16

---

2.3. Curcumin as anti-malarial agent	21
2.4. Pyrazole and hexahydraindazole as antimicrobial agent	27
2.5. Glucosamine-6-phosphate synthase: a novel target for antimicrobial agents	34
2.6. Curcumin and MMP	35
<b>Chapter 3: RATIONALE OF APPROACH</b>	<b>37</b>
<b>Chapter 4. PLAN OF STUDY</b>	
4.1. Design and synthesis of curcumin analogues	41
4.2. Characterization of synthesized compounds by using modern analytical tools	41
4.3. Evaluation of <i>In vitro</i> antimicrobial activity of synthesized compounds	41
4.4. Molecular docking study of synthesized compounds against antimicrobial target Glucosamine-6-phosphate synthase	41
4.5. Evaluation of <i>In vitro</i> anti-malarial activity of synthesized compounds	41
4.6. Quantitative structure activity relationship (QSAR) study of synthesized compounds	41
<b>Chapter 5. EXPERIMENTAL</b>	
5.1. General procedure for the synthesis of hexahydroindazole analogues of curcumin(A1-B5)	42
5.2. General procedure for synthesis of pyrazole analogues of curcumin (CP1-CP14)	43
5.3. General procedure for synthesis of cycloheptanones analogues of curcumin (C1-C14)	45
5.4. <i>In-vitro</i> anti microbial study of curcumin analogues	46
5.5. <i>In-vitro</i> anti-malarial study of curcumin analogues	46
5.6. Molecular docking study of curcumin analogues against	

---

---

antimicrobial target Glucosamine-6-phosphate synthase	48
5.7. Quantitative Structure Activity Relationship (QSAR) study for curcumin analogue as antimicrobial agent	48
<b>Chapter 6. RESULTS AND DISCUSSION</b>	
6.1. Characterization of synthesized Compounds	52
6.1.1 Synthesis and characterization of hexahydroindazole analogues of curcumin	53
6.1.2. Synthesis and characterization of pyrazole analogues of curcumin	60
6.1.3. Synthesis and characterization of cycloheptanones analogues of curcumin	66
6.2. <i>In vitro</i> antimicrobial screening of curcumin analogues	72
6.2.1. <i>In vitro</i> antimicrobial screening of hexahydroindazole analogues of curcumin	72
6.2.2. <i>In vitro</i> antimicrobial study of pyrazole analogues of curcumin	75
6.2.3. <i>In vitro</i> antimicrobial study of cycloheptanone analogues of curcumin	78
6.3. Antimalarial screening of curcumin analogues	80
6.3.1. Cytotoxicity study of curcumin analogues active against HepG2 line cells	83
6.3.2 Comparison of anti-malarial activity and cytotoxicity on basis of selectivity index	84
6.4. <i>In silico</i> study of analogues of curcumin	85
6.4.1. Molecular Docking study of hexahydroindazole analogues of curcumin	86
6.4.2. Molecular Docking study of pyrazole analogues of curcumin	89
6.5. Quantitative structure activity relationship (QSAR) study of synthesized compounds	93
6.5.1. Quantitative structure activity relationship (QSAR) study	93
<b>Chapter 7. CONCLUSIONS</b>	112
SUMMARY	116
REFERENCES	119

---